Phase III Trial of a Humanized Anti-CD33 Antibody (HuM195) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Trial Watch: Monoclonal antibodies in cancer therapy

“…118 Of note, naked lantuzumab has previously been tested in phase III clinical trials, but failed to yield statistically significant improvements in response rates and patient survival. 119,120 Another CD33-targeting immunoconjugate, gemtuzumab calicheamicin, is approved since 2000 for the treatment of acute myeloid leukemia ( Table 2), possibly explaining why the interest in lantuzumab appears to be decreasing.…”

Targeted use of Alpha Particles: Current Status in Cancer Therapeutics

“…The concept of antibody mediated therapy has played a major role in hematologic malignancies in the past few years. The humanized anti CD33 antibody HuM195 have been used in relapsed acute myeloid leukemia with minimal overall response and complete response achieved only in patients with low disease bulk [50], to increase the potency of above antibodies conjugation with targeted radiotherapy offers a particular strategy that helps overcoming tumor antigen heterogeneity. The choice of the appropriate isotope depends on its half life, biologic properties and ability to provide the maximum treated effect with minimal possible toxicity.…”

Expression of an anti-CD33 single-chain antibody by Pichia pastoris

“…A number of anti-CD33 antibodies (Abs) have already been developed as potential immunotherapeutic agents for AML, used alone (Gibson, 2002;Caron et al, 1998) or infused with cytokines (Caron et al, 1995;Kossman et al, 1999), conjugated to radioisotopes (Jurcic et al, 1995(Jurcic et al, , 2002, immunotoxins (Pagliaro et al, 1998), other antibodies (bispecific Abs) (Balaian and Ball, 2001) and most successfully to the anti-tumour antibiotic calicheamicin, known as Mylotargk (Tomblyn and Tallman, 2003). These therapies have concentrated on the use of whole IgG molecules, whereas increasingly, smaller engineered antibody fragments such as the single-chain variable fragments (scFv) are being developed for a number of applications such as: tumour imaging (Begent et al, 1996;Goel et al, 2001), cancer therapy (Kikuchi et al, 2004;Tur et al, 2003), molecular immunolabelling (Malecki et al, 2002), and diagnostics (Peipp et al, 2004).…”